Inhaled Iloprost for Suspected COVID-19 Respiratory Failure

• Status: Recruiting
• Trial end date: 2021-05-31
• Target enrollment: 0
• Participant gender: All

Summary

Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is thought to be the main cause of respiratory failure in COVID-19 patients. Research is still ongoing to further elucidate the different ARDS subtypes that may exist in COVID-19. It is crucial to find new targets for treatment and support of COVID-19 patients with respiratory failure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamad Medical Corporation
• Treatments: Iloprost

Criteria

Inclusion Criteria:

1. Suspected or confirmed COVID-19 patient by PCR

2. O2 saturation =<92% on 5 or more l/min of O2 by NC or Face mask

3. On CPAP, HFNC or Invasive ventilation

4. Enrollment within 48h of onset of hypoxemia

Exclusion Criteria:

1. Age <18

2. Pregnancy or Positive pregnancy test at the time of screening

3. Clinical evidence of left atrial hypertension or known chronic CHF

4. Persistent Hypotension SBP<85 on presentation

5. Mechanical ventilation >7 days

6. Patients who received iloprost treatment for any indication within 48 hours prior to enrollment in the clinical trial or patients who were on thrombin inhibitors, or nitric oxide within the previous 24 h before study randomization are also excluded.

7. Patients with contraindication for ilioprost